证券代码：002020 证券简称：京新药业 公告编号：2025016 浙江京新药业股份有限公司 第八届监事会第十一次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司第八届监事会第十一次会议通知于2025年3月21 日以电子邮件形式发出，会议于2025年4月1日在杭州总部7号楼一楼会议室召 开。会议应到监事3名，实到3名，符合《公司法》和《公司章程》的有关规 定。会议由监事会主席胡天庆主持，会议审核并一致通过了如下决议： 1、以3票同意、0票反对和0票弃权的表决结果，审核通过了《公司2024年 度监事会工作报告》。 2、以3票同意、0票反对和0票弃权的表决结果，审核通过了《公司2024年 年度报告及其摘要》。 监事会认为：董事会编制和审核浙江京新药业股份有限公司2024年年度报 告的程序符合法律、行政法规、中国证监会和深圳证券交易所的规定，报告内 容真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 7、以3票同意、0票反对和0票弃权的表决结果，审核通过了《关于开展外 汇套期保值业务的议案 ...

证券代码：002020 证券简称：京新药业 公告编号：2025015 浙江京新药业股份有限公司 第八届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）第八届董事会第十四次 会议通知于 2025 年 3 月 21 日以电子邮件形式发出，会议于 2025 年 4 月 1 日在杭州总部 7 号楼二楼会议室以现场会议的方式召开。会议应到董事 9 名， 实到董事 9 名，公司监事及高级管理人员列席了会议，符合《公司法》及《公 司章程》的有关规定。会议由董事长吕钢先生主持，会议经表决形成如下决 议： 一、以 9 票同意、0 票反对和 0 票弃权的表决结果，审议通过了《公司 2024 年度总裁工作报告》。 二、以 9 票同意、0 票反对和 0 票弃权的表决结果，审议通过了《公司 2024 年度董事会工作报告》，该议案需提交公司 2024 年度股东大会审议。《公 司 2024 年度董事会工作报告》详见公司刊登在巨潮资讯网 http://www.cninfo.com.cn 上的《2024 年年度报告》之"第三节 ...

Financial Performance - The company's operating revenue for 2024 reached ¥4,158,550,673.09, representing a 3.99% increase compared to ¥3,998,835,219.87 in 2023[21] - Net profit attributable to shareholders increased by 15.04% to ¥711,961,458.77 in 2024 from ¥618,898,033.74 in 2023[21] - The net profit after deducting non-recurring gains and losses rose by 21.38% to ¥647,009,586.63 in 2024 compared to ¥533,039,855.27 in 2023[21] - Basic earnings per share increased by 15.28% to ¥0.83 in 2024 from ¥0.72 in 2023[21] - Total assets at the end of 2024 amounted to ¥8,479,313,218.60, a 6.17% increase from ¥7,986,556,907.16 at the end of 2023[21] - The company's net assets attributable to shareholders grew by 8.29% to ¥5,969,508,653.97 at the end of 2024 from ¥5,512,374,486.23 at the end of 2023[21] - Cash flow from operating activities decreased by 8.41% to ¥726,161,370.81 in 2024 from ¥792,838,365.93 in 2023[21] - The weighted average return on equity increased by 0.79 percentage points to 12.45% in 2024 from 11.66% in 2023[21] Revenue Breakdown - The company achieved a total revenue of 4.16 billion yuan in 2024, representing a year-on-year growth of 3.99%[64] - The revenue from finished pharmaceuticals was 2.52 billion yuan, an increase of 8.42% year-on-year, while raw material drug revenue decreased by 8.37% to 876 million yuan[57] - The medical device segment generated revenue of 687 million yuan, marking a year-on-year growth of 7.84%[61] - The company's main business revenue reached ¥4,085,821,269.79, an increase of 4.23% year-on-year, with a gross margin of 50.05%[66] - The pharmaceutical manufacturing segment generated revenue of ¥3,398,588,387.64, with a gross margin of 53.11%, reflecting a 3.53% increase in revenue year-on-year[66] Research and Development - The company invested 383 million yuan in R&D, focusing on innovative drugs, including the successful clinical trial progress of JX11502MA capsules[59] - The company has a robust R&D strategy focusing on innovative drugs in the CNS and cardiovascular fields, with a pipeline that includes over 10 ongoing innovative drug projects[50] - The company has accumulated a total of 222 patents, including 156 invention patents, reflecting its strong R&D capabilities and innovation[47] - The company aims to enhance its CNS pipeline with new products, including JX11502MA capsules and other innovative drugs currently in clinical trials[75] - The company is focusing on expanding its product line and enhancing competitiveness through the development of generic drugs and new technologies[75] Market Position and Strategy - The company has established a strong market position in the CNS field, with the innovative drug Jingnuoning® (Dazisni Capsule) expected to launch in March 2024 and enter the medical insurance payment directory by November 2024[43] - The company has a complete pharmaceutical industry chain from raw materials to finished products, enhancing its cost advantages and market competitiveness[51] - The company has a well-established marketing network covering commercial channels, retail pharmacies, and hospitals, with a growing presence in e-commerce platforms[52] - The company is actively involved in the development of medical devices, including customized medical displays and imaging solutions[34] - The company aims to improve internal management quality and operational efficiency to achieve healthy growth in revenue and net profit[31] Operational Efficiency - The company adopts a sales-driven production model, maintaining appropriate safety stock and formulating annual and monthly production plans based on sales forecasts[36] - The overall product structure has been optimized, leading to stable growth in the profitability of the main business[33] - The company has established a procurement model that combines centralized purchasing and subsidiary self-purchasing to ensure quality and cost control[35] - Sales expenses decreased by 11.65% to ¥692,264,053.54, attributed to improved efficiency and enhanced cost control[74] - The company's inventory increased by 33.14% year-on-year to ¥364,023,295.62, primarily due to increased procurement for centralized purchasing[67] Corporate Governance - The company maintains an independent governance structure, with a board of nine directors, including three independent directors, ensuring compliance with legal requirements[114] - The company has established a performance evaluation and incentive mechanism for its directors and managers, promoting transparency and compliance with regulations[117] - The company operates independently from its controlling shareholder in terms of business, personnel, assets, and financial management, ensuring complete operational autonomy[122] - The company has a dedicated internal audit department to oversee financial reporting and internal controls, ensuring compliance and risk management[120] - The company has not experienced any significant deviations from the governance standards set by regulatory authorities[121] Environmental Responsibility - The company has implemented environmental protection policies in compliance with national laws and regulations[175] - The company has a commitment to prioritize environmental protection while developing its production capabilities[175] - The company has established two wastewater treatment plants with a total daily processing capacity of 1,600 tons, utilizing a comprehensive treatment process to ensure compliance with discharge standards[179] - The company has invested CNY 45.115 million in environmental governance and protection for the year 2024, and paid CNY 287,000 in environmental protection tax[184] - The company has no major environmental issues and is not listed as a key pollutant discharge unit by environmental authorities[175] Employee and Talent Management - The total number of employees at the end of the reporting period is 3,869, with 1,312 in the parent company and 2,557 in major subsidiaries[154] - The company allocated 2.5 million RMB for training in 2024, with a total of 16,314 training participants and 36,364.6 training hours[157] - The company has implemented a performance evaluation system for senior management, assessing based on work ability and completion of objectives[162] - The company has a competitive compensation and benefits system to attract and retain talent, aligned with national laws and regulations[156] - The company is focused on talent development to match its growth needs, implementing internal training and external recruitment strategies[107] Legal and Compliance - The company has not faced any penalties or rectification issues during the reporting period[200] - The company has made changes to its accounting policies in accordance with new regulations issued by the Ministry of Finance, effective January 1, 2024, which will not significantly impact its financial status[193] - The company has engaged Lixin Certified Public Accountants for internal control audit services at a cost of 200,000 CNY[196] - There are ongoing arbitration proceedings with Youlin Biotechnology Co., Ltd., with a claim amount of 8,029,100 CNY, which has been recognized as a liability[199] - The company has filed for international commercial arbitration seeking compensation of 12,282,100 CNY plus interest from Youlin Biotechnology[199]

证券代码：002020 证券简称：京新药业 公告编号：2025017 2025年4月1日，浙江京新药业股份有限公司（以下简称"公司"）召开第八 届董事会第十四次会议、第八届监事会第十一次会议，分别审议通过了《公司2024 年度利润分配预案》，该议案尚需提交公司2024年度股东大会审议通过后方可实 施。 二、利润分配预案基本情况 经立信会计师事务所（特殊普通合伙）审计，本公司 2024 年度实现净利润 711,961,458.77 元（合并报表），根据《公司法》和《公司章程》的有关规定， 按母公司净利润 963,649,307.72 元提取 10%的法定盈余公积 96,364,930.77 元， 加上上年度转入本年度可分配利润 2,540,093,920.60 元，减去 2023 年度分红款 258,308,742.00 元，公司本年度可供股东分配的利润累计 2,897,381,706.60 元。 公司 2024 年度利润分配预案为：以截止 2024 年 12 月 31 日公司总股本 861,029,140 股扣除回购专户上已回购股份后的股本为基数，按分配比例不变的 原则，向全体股东每 10 股派发现金红利 3 ...

证券代码：002020 证券简称：京新药业 公告编号：2025013 关于股份回购进展公告 浙江京新药业股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、回购股份方案的基本情况 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.8 元/股（含），若按回购总金额上、下 限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 》 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、回购股份的基本情况 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 35,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.8 元/股（含），若按回购总金额上、下 限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 》 、 《 中 国 证 券 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《关 ...

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.96% on March 7, 2025, underperforming the CSI 300 Index by 0.65 percentage points, ranking 22nd among 31 sub-industries [4]. - The approval of ARS's Neffy (1 mg epinephrine nasal spray) by the FDA marks a significant innovation in the delivery method for treating type I allergic reactions in children aged 4 and above, representing the first major advancement in 35 years for this patient group [5][9]. - Notable stock performances included Aosaikang (+9.99%), Yipinhong (+9.77%), and Rejing Biology (+8.84%) on the gainers' list, while Aopumai (-6.26%), Puri Eye (-5.97%), and BGI (-4.86%) led the decliners [4]. Summary by Sections Market Performance - As of March 7, 2025, the pharmaceutical sector's performance was -0.96%, with sub-sectors like in vitro diagnostics (-0.43%) and blood products (-0.72%) performing better, while hospitals (-2.11%) and medical devices (-1.67%) lagged [4]. Industry News - The FDA's approval of Neffy is a pivotal development for the treatment of severe allergic reactions in children, highlighting the ongoing innovation in the pharmaceutical industry [5]. - Companies such as Jingxin Pharmaceutical announced an increase in their share repurchase plan, raising the total amount from a minimum of 200 million RMB to 350 million RMB [5]. - Nouvegen and BGI have entered a strategic cooperation agreement to leverage their respective expertise in reproductive genetics, tumor prevention, chronic disease management, and infection control [5]. Company News - Heng Rui Pharmaceutical received approval for clinical trials of several new drugs, indicating ongoing research and development efforts [6]. - Kanglong Chemical reported the completion of a share reduction plan, with a total of 10,666,716 shares reduced, representing 0.60% of the company's total share capital [6].

证券代码：002020 证券简称：京新药业 公告编号：2025011 浙江京新药业股份有限公司 关于调整回购股份方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 1、本次调整回购股份方案的具体内容：将回购资金总额由"不低于人民币 20,000万元(含)，不超过人民币40,000万元（含）"调整至"不低于人民币35,000 万元(含)，不超过人民币70,000万元（含）"。 2、除上述事项调整外，回购股份方案的其他内容未发生变化。 3、本次调整回购股份方案事项已经公司第八届董事会第十三次会议审议通 过，无需提交股东大会审议。 4、相关风险提示：本次回购股份方案存在因回购期限内公司股票价格持续 超出回购方案披露的价格上限等原因，导致回购方案无法顺利实施或只能部分实 施的风险；回购股份用于实施股权激励或员工持股计划，可能存在因股权激励或 员工持股计划未能经公司董事会、股东大会等决策机构审议通过、持股对象或激 励对象放弃认购等原因，导致已回购股份无法授出或无法全部授出而被注销的风 险；存在回购期限内因对本公司股票交易价格产生重大影响的重大事项发生 ...

证券代码：002020 证券简称：京新药业 公告编号：2025010 浙江京新药业股份有限公司 第八届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 1、以 9 票同意、0 票反对和 0 票弃权的表决结果，审议通过了《关于 调整回购股份方案的议案》。 基于对公司未来业务发展、市场价值等方面的信心，为切实推进公司回购 股份事项的顺利实施，保障投资者利益，综合考虑证券市场变化，公司调整本 次回购资金总额。将回购资金总额由"不低于人民币 20,000 万元(含)，不超过 人民币 40,000 万元（含）"调整至"不低于人民币 35,000 万元(含)，不超过人 民币 70,000 万元（含）"。除调整回购资金总额外，本次回购股份方案的其他 内容未发生变化。详见公司在《证券时报》、《中国证券报》和巨潮资讯网 http://www.cninfo.com.cn 上刊登的 2025011 号公告。 特此公告。 浙江京新药业股份有限公司董事会 2025 年 3 月 8 日 浙江京新药业股份有限公司(以下简称"公司")第八届董事会第十三次会 议通知于 2 ...

证券代码：002020 证券简称：京新药业 公告编号：2025009 浙江京新药业股份有限公司 关于回购公司股份比例达到 3%暨回购进展的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江京新药业股份有限公司(以下简称"公司")于 2025 年 1 月 8 日召开的 第八届董事会第十二次会议，审议通过了《关于股份回购的方案》，公司使用自 有资金以集中竞价交易方式回购公司股份，回购的公司股份将用于股权激励或员 工持股计划。本次回购总金额为不低于人民币 20,000 万元(含)，不超过人民币 40,000 万元（含），回购价格不超过 14.8 元/股（含），若按回购总金额上、下 限和回购股份价格上限测算，预计回购股份数量约为 1,351 万股-2,703 万股， 约占目前公司总股本的 1.57%-3.14%。具体回购金额及回购数量以回购完成时实 际使用的资金和回购的股份数量为准。回购股份的实施期限自董事会审议通过本 次回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 1 月 9 日、2025 年 1 月 10 日 在 《 证 券 时 报 》 ...